Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

However, many health outcomes, like nausea and vomiting, saw their risks increase with GLP-1 use. Glucagon-like peptide-1 receptor agonist use corresponded with risk reductions for dozens of ...

Share on Pinterest Women with diabetes may get the strongest cardiovascular protection from GLP-1 agonists ... high blood pressure, nerve and eye damage, and kidney disease.

Their findings published in Nature Medicine on Monday suggest that GLP-1 use is linked to beneficial ... Meanwhile, gastrointestinal disorders, low blood pressure, arthritis, and pancreatitis ...

A new study suggests that weight loss and diabetes treatment may represent only a small sample of the potential uses of GLP-1 drugs.

Employers face significant financial risk when investing in costly GLP-1 treatments, as employees who discontinue the medication without sustainable behavior changes may regain the weight ...